Czech/SlovakiaCzech RepublicSlovakia

New Instrument Gives Tax Breaks for R&D in the Czech Republic

10.12.2004

Prague - At the beginning of November the Czech Government has passed a new income tax law providing tax benefits for research and development (R&D) in the Czech Republic. The Chamber of Deputies voted 'Yes' on the modified bill which introduces a deductible item of 100% of costs allocated for R&D. The bill now has to be affirmed by the senate. The new legislation will then come into force on January 1, 2005. The essence of the support resides in the fact that R&D costs, which can be regularly declared for tax purposes and included in every company's costs, will now be eligible to be deducted once more at 100% from the calculated tax base. The deductible item is thus seen as an effective tax instrument to support R&D. “It will provide major support to companies operating in the Czech Republic and will contribute to a higher competitiveness of our country,” commented Martin Jahn, Deputy Prime Minister for Economic Affairs.
The introduction of new tax breaks for R&D aims at increasing the attractiveness of the Czech Republic as a country suitable for such R&D activities. The approval should help after the phase of foreign investors' arrival to retain the Czech Republic's attractiveness not only in terms of low operating and labour costs but also in terms of introducing activities with a higher added value.
The new legislation is also seen as one step towards satisfying the need to strengthen the EU's competitiveness, which the Czech Republic assumed as part of the so-called Lisbon strategy.

Czech/SlovakiaCzech RepublicSlovakia

24.09.2007

Prague/Norwood – The international clinical trial company Medpace Inc. (Norwood, USA) has acquired the Czech contract research organisation Monax s.r.o. (Prague) for an undisclosed sum. With the acquisition, which the firm...

Czech/SlovakiaCzech RepublicSlovakia

11.07.2007

Prague/Foster City – An oligonucleotide analogon, originally developed at the Institute of Organic Chemistry and Biochemistry (IOCB) at the Czech Academy of Sciences in Prague, has entered clinical testing as treatment for...

Czech/SlovakiaCzech RepublicSlovakia

17.05.2007

Prague/Leuven – The Czech Republic is lagging behind in applying the ten year-old European convention on Human rights and biomedicine, according to a new report from EuroGentest, an EU-funded Network of Excellence, which assesses...

Czech/SlovakiaCzech RepublicSlovakia

21.11.2006

BIOTEC 2006, the first international biotechnology conference and exhibition in Eastern Europe, held at the end of October, staged the official inauguration ceremony of the International Clinical Research Center (ICRC). The...

Czech/SlovakiaCzech RepublicSlovakia

16.09.2006

In order to keep track of developments and to promote network-creation, for both domestic-domestic and domestic-foreign cooperations the South Moravian Innovation Centre, Brno, has conducted the Czech Republic’s first...

Czech/SlovakiaCzech RepublicSlovakia

21.07.2006

Bratislava – In late-April, the Slovak government authorized field trials with genetically modified MON 810 maize at three undisclosed locations. The total area of the field trials is approximately 30 hectares. Although Slovakia...

Czech/SlovakiaCzech RepublicSlovakia

21.07.2006

Pruhonice – Biomass production is a promising alternative for the Czech Republic’s agricultural sector. Biomass could cover the annual domestic bio-energy demand of 250 PJ (predicted for 2030), and could be exported as bio-fuels...

Czech/SlovakiaCzech RepublicSlovakia

12.05.2006

Prague - The French pharma giant Sanofi-Aventis S.A. strengthened its generics business in Central and Eastern Europe (CEE) with a participation in the Czech generics producer Zentiva a.s. According to Sanofi-Aventis, the company...

Czech/SlovakiaCzech RepublicSlovakia

12.05.2006

Brno - The International Clinical Research Center (ICRC) in Brno, will collaborate with the renowned Mayo Clinic in Rochester, MN, to establish a clinical and research education center that meets the challenges of 21st-century...

Czech/SlovakiaCzech RepublicSlovakia

17.03.2006

Humpolec - A product derived from genetically modified potatos with altered starch composition poses no threat to human health, according to a European Food Safety Authority (EFSA) panel ruling.BASF Plant Science's GM potato,...

Displaying results 31 to 40 out of 70

< Previous 31-40 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-czech-slovakia/browse/3/article/new-instrument-gives-tax-breaks-for-rd-in-the-czech-republic.html

Stock list

All quotes

TOP

  • ADDEX (CH)4.29 CHF18.51%
  • COSMO PHARMACEUTICALS (CH)179.10 CHF7.76%
  • NEUROVIVE PHARMACEUTICAL AB (S)55.75 SEK6.19%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • BAVARIAN NORDIC (D)15.82 EUR-8.02%

TOP

  • SANTHERA (CH)72.80 CHF137.5%
  • CELLECTIS (F)13.63 EUR103.4%
  • ADDEX (CH)4.29 CHF92.4%

FLOP

  • THROMBOGENICS (B)8.92 EUR-50.4%
  • MERCK KGAA (D)64.16 EUR-50.1%
  • VERONA PHARMA (UK)1.20 GBP-43.4%

TOP

  • SANTHERA (CH)72.80 CHF3576.8%
  • GW PHARMACEUTICALS (UK)444.50 GBP828.4%
  • IXICO (UK)55.50 GBP320.5%

FLOP

  • EVOCUTIS (UK)0.21 GBP-93.3%
  • CYTOS (CH)0.25 CHF-92.8%
  • THROMBOGENICS (B)8.92 EUR-72.4%

No liability assumed, Date: 09.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events

Partner-Events

Vilnius (LT)

Life Sciences Baltics